Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 29
Healthy volunteers: yes

Brief summary:
The main purpose of this study is to investigate the safety of the study drug known as LY3039478 and evaluate two different formulations of LY3039478 in healthy participants. Part A has three periods. Either LY3039478 or placebo will be given once by mouth in each period. Part B has two periods. Participants will receive both formulations of LY3039478, by mouth, over the course of the study. Both parts of the study will also explore how much LY3039478 gets into the bloodstream and how long it takes the body to get rid of it. Information about any side effects will also be collected. Participants may only enroll in one part. The study will last at least 33 days, not including screening. Screening must be performed up to 30 days before enrollment.

Part B was added by protocol amendment approved in April, 2016.

Detailed description:

Arms:
arm 1: Single oral dose of placebo administered in one of three study periods arm 2: Escalating single oral dose of 25 milligram (mg), 50 mg, and 75 mg capsule formulation (formulation 3) LY3039478 administered in two of three study periods arm 3: Single oral 50 mg dose of drug-in capsule (reference, formulation 1) LY3039478 administered in one of two study periods arm 4: Single oral 50 mg dose of formulated capsule (test, formulation 3) LY3039478 administered in one of two study periods

Interventions: intervention 1: Placebo intervention 2: LY3039478 Capsule Formulation (Formulation 3) intervention 3: LY3039478 Drug-in Capsule (Reference, Formulation 1) intervention 4: LY3039478 Formulated Capsule (Test, Formulation 3)
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally intervention 3: Administered orally intervention 4: Administered orally

Protocol document: